medigraphic.com
ISSN 1817-5996 (Electronic)

2020, Number 3

<< Back Next >>

Rev Cub de Reu 2020; 22 (3)

Managing foot ulcers as a clinical manifestation of systemic sclerosis

Urbano ZAP, Calapaqui RKA, Villavicencio HKG, Guevara LDA, Morales SJL

Language: Spanish
References: 29
Page:
PDF size: 402.42 Kb.


ABSTRACT

Ulcers can occur on bony bumps, such as the proximal phalanges or elbows, but are more likely to be secondary to tight skin and trauma and not responsive to vasodilator therapy. All ulcers are characteristically very painful. To present aspects related to the management of digital ulcers in scleroderma based on the experience of different authors. The management of digital ulcers in scleroderma includes non-pharmacological, pharmacological and surgical intervention. The use of nitrates, infusions of acetylcysteine, Vitamin E Gel, among other methods, improve the healing time in patients with scleroderma. The lack of US Food and Drug Administration approved therapies for digital ulcerations ensures a renewed focus and attention on finding meaningful treatment options. Clinicians should employ a multi-faceted therapeutic approach to optimize existing digital ulcers treatment and avoid new lesion formation to provide patients with the best quality of life.


REFERENCES

  1. Denton CP, Korn JH. Digital ulceration and critical digital ischaemia in scleroderma. Scleroderma Care Res. 2003;1:12-6.

  2. Baron M. Consensus opinion of a North American Working Group regarding the classification of digital ulcers in systemic sclerosis. Clin Rheumatol. 2014;33(2):207-14.

  3. Sunderkotter C, Hergott I, Bruckner C. Comparison of patients with and without digital ulcers in systemic sclerosis: detection of possible risk factors. Br J Dermatol. 2009;160:835-43.

  4. Hachulla E, Clerson P, Launay D. Natural history of ischemic digital ulcers in systemic sclerosis: a single-center retrospective longitudinal study. J Rheumatol. 2007;34:2423-30.

  5. Steen V, Denton CP, Pope JE, Matucci-Cerinic M. Digital ulcers: overt vascular disease in systemic sclerosis. Rheumatology. 2009;48:19-24.

  6. Ferri C, Sebastiani M, Lo Monaco. Systemic sclerosis evolution of disease pathomorphosis and survival. Our experience on Italian patients' population and review of the literature. Autoimmun Rev. 2014;13(10):1026-34. doi: https//:10.1016/j.autrev.2014.08.029

  7. van der Leeden M, Steultjens M, Dekker JH, Prins AP, Dekker J, et al. Forefoot joint damage, pain and disability in rheumatoid arthritis patients with foot complaints: the role of plantar pressure and gait characteristics. Rheumatology. 2006;45:465-9.

  8. Dalal S, Widgerow AD, Evans GR. The plantar fat pad and the diabetic foot - A review. Int Wound J. 2013;12:1742-1801.

  9. Shanmugam VK, Price P, Attinger CE, Steen VD. Lower Extremity Ulcers in Systemic Sclerosis: Features and Response to Therapy. Int J Rheumatol. 2010.

  10. Sari-Kouzel H, Hutchinson CE, Middleton A, Webb F, Moore T, et al. Foot problems in patients with systemic sclerosis. Rheumatology. 2001;40:410-3.

  11. Reiber GE, Vileikyte L, Boyko EJ, del Aguila M, Smith DG, et al. Causal pathway for in incident lower extremity ulcers in patients with foot ulcer from two setting. Diabetes Care. 1995;1:157-62.

  12. Alcacer-Pitarch B, Buch MH, Gray J, Denton CP, Herrick A, et al. Pressure and pain in scleroderma an evaluation of simple intervention (PISCES): randomized controlled trial protocol. BMC Musculoskeletal Disord. 2012;13:11.

  13. Crawford F, Inkster M, Kleijnen J, Fahey T. Predicting foot ulcers in patients with diabetes: A systematic review and meta-analysis. QJM. 2007;100:65-86.

  14. Reidy ME, Steen V, Nicholas J. Lower extremity amputation in scleroderma. Arch Phys Med Rehabil. 1992;73:811-13.

  15. Chathra N, Bhat RM. Corn in scleroderma. Indian Dermatol Online J. 2017;8:49-50.

  16. Thompson AE, Pope JE. Calcium channel blockers for primary Raynaud's phenomenon: A meta-analysis. Rheumatology. 2005;44:145-50.

  17. Gore J, Silver R. Oral sildenafil for the treatment of Raynaud's phenomenon and digital ulcers secondary to systemic sclerosis. Ann Rheum Dis. 2005;64(9):1387.

  18. Caglayan E, Huntgeburth M, Karasch T. Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud's disease. Arch Intern Med. 2006;166(2):231-3.

  19. Garcia de la Pena-Lefebvre P, Rodriguez Rubio S, Valero Expositio M. Long term experience of bosentan for treating ulcers and healed ulcers in systemic sclerosis patients. Rheumatology (Oxford). 2008;47:464-6.

  20. Anderson ME, Moore TL, Hollis S, Jayson MIV, King TA, Herrick AL. Digital vascular response to topical glyceryl trinitrate, as measured by laser Doppler imaging, in primary Raynaud's phenomenon and systemic sclerosis. Rheumatology. 2002;41(3):324-8.

  21. Sambo P, Amico D, Giacomelli R. Intravenous N-acetylcysteine for treatment of Raynaud's phenomenon secondary to systemic sclerosis: a pilot study. J Rheumatol. 2001;28(10):2257-62.

  22. Fiori G, Galluccio F, Braschi F. Vitamin E gel reduces time of healing of digital ulcers in systemic sclerosis. Clin Exp Rheumatol. 2009;27(3):51-4.

  23. Matsumoto Y, Ueyama T, Endo M. Endoscopic thoracic sympathectomy for Raynaud's phenomenon. J Vasc Surg. 2002;36(1):57-61.

  24. Momeni A, Sorice S, Valenzuela A. Surgical treatment of systemic sclerosis - is it justified to offer peripheral sympathectomy earlier in the disease process? Microsurgery. Epub 2015 Jan 14. doi: https://10.1002/micr.22379

  25. Iorio M, Masden D, Higgins J. Botulinum toxin a treatment of Raynaud's phenomenon: A review. Semin Arthritis Rheum. 2012;41:599-603.

  26. Uppal L, Dhaliwal K, Butler PE. A prospective study of the use of botulinum toxin injections in the treatment of Raynaud's syndrome associated with scleroderma. J Hand Surg. 2014;39:876-80.

  27. Granel B, Daumas A, Jouve E. Safety, tolerability and potential efficacy of injection of autologous adipose-derived stromal vascular fraction in the fingers of patients with systemic sclerosis: An open-label phase 1 trial. Ann Rheum Dis. Epub 2014 Aug 11. doi: http://10.1136/annrheumdis-2014-205681.

  28. Del Bene MD, Pozzi MR, Rovati L. Autologous fat grafting for scleroderma-induced digital ulcers. An effective technique in patients with systemic sclerosis. Handchir Mikrochir Plast Chir. 2014;46:242-7.

  29. Taylor MH, McFadden JA, Bolster MB. Ulnar artery involvement in systemic sclerosis (scleroderma). J Rheumatol. 2002;29(1):102-6.




2020     |     www.medigraphic.com